Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

What Will the Average American Pay for Obamacare in 2018?
What Will the Average American Pay for Obamacare in 2018?
Big changes are in store for consumers who are planning to purchase an Obamacare (officially the Affordable Care Act, or ACA) plan in 2018. Though the enrollment period is ongoing and remains the....
3 Top Diabetes Stocks to Buy Now
3 Top Diabetes Stocks to Buy Now
Diabetes is huge problem for Americans. Between 1990 and 2010, the number of U.S. residents with diabetes tripled, and the number of new cases annually doubled. Both prevalence and costs....
The Federal Government Just Broke Its Medical-Marijuana Promise
The Federal Government Just Broke Its Medical-Marijuana Promise
Few if any industries are growing at a quicker and more consistent pace in the U.S. than marijuana. A report released earlier this year by Marijuana Business Daily entitled "Marijuana Business....
5 Cancer Types With the Poorest Long-Term Outlook
5 Cancer Types With the Poorest Long-Term Outlook
There's arguably no scarier diagnosis a patient can receive from their doctor than cancer. But the grim reality, based on data from the National Cancer Institute's Surveillance, Epidemiology, and....
How to Diversify Your Healthcare Investments
How to Diversify Your Healthcare Investments
On this week's episode of Industry Focus: Healthcare, analysts Kristine Harjes and Todd Campbell get back to basics and explain what you need to know about diversifying your portfolio, especially....
How to Diversify Your Healthcare Investments
How to Diversify Your Healthcare Investments
On this week's episode of Industry Focus: Healthcare, analysts Kristine Harjes and Todd Campbell get back to basics and explain what you need to know about diversifying your portfolio, especially....
Why Collegium Pharmaceutical Shares Are Tumbling 12.9% Today
Why Collegium Pharmaceutical Shares Are Tumbling 12.9% Today
After FDA commissioner Scott Gottlieb issued a statement suggesting an easier path to winning approval for generic opioids that are abuse deterrent, shares in Collegium Pharmaceutical's (NASDAQ:....
Mazor Robotics Might Need to Worry About This Potential Rival the Most (Hint: It's Not Intuitive Surgical)
Mazor Robotics Might Need to Worry About This Potential Rival the Most (Hint: It's Not Intuitive Surgical)
When it comes to the use of robots in spine surgery, Mazor Robotics (NASDAQ: MZOR) clearly has the early-mover advantage. The Israel-based company claims more than 170 surgical robot systems....
Why Marijuana Stock GW Pharmaceuticals Skyrocketed 11% Today
Why Marijuana Stock GW Pharmaceuticals Skyrocketed 11% Today
After the company released updated clinical trial data showing efficacy of its marijuana drug as a monotherapy and improvement from baseline over long-term use, shares of GW....
Why OraSure Technologies, Inc. Zoomed Higher Today
Why OraSure Technologies, Inc. Zoomed Higher Today
OraSure Technologies (NASDAQ: OSUR) is up 18.6% at 3:42 p.m. EST Tuesday after the company announced that it entered into a $143 million agreement to supply its Oragene devices to an undisclosed....
Agilent Technologies (A) Q4 2017 Earnings Conference Call Transcript
Agilent Technologies (A) Q4 2017 Earnings Conference Call Transcript
Image source: The Motley Fool.Agilent Technologies (NYSE: A) Q4 2017 Earnings Conference CallNov. 20, 2017 4:30 p.m. ETOperatorContinue readingSource: Fool.com
NxStage Medical Prepares for Fresenius Merger
NxStage Medical Prepares for Fresenius Merger
NxStage Medical (NASDAQ: NXTM) is in an awkward position right now, and it's one that any investor in a company that has received an acquisition bid can understand. The maker of home dialysis....
The 1 Thing Missing From Gilead Sciences' 2018 Priority List
The 1 Thing Missing From Gilead Sciences' 2018 Priority List
At a recent healthcare conference, Gilead Sciences (NASDAQ: GILD) CEO John Milligan laid out his top three priorities for 2018. Here's what he said (this and all other quotes courtesy of S&P....
The 1 Thing Missing From Gilead Sciences' 2018 Priority List
The 1 Thing Missing From Gilead Sciences' 2018 Priority List
At a recent healthcare conference, Gilead Sciences (NASDAQ: GILD) CEO John Milligan laid out his top three priorities for 2018. Here's what he said (this and all other quotes courtesy of S&P....
The 1 Thing Missing From Gilead Sciences' 2018 Priority List
The 1 Thing Missing From Gilead Sciences' 2018 Priority List
At a recent healthcare conference, Gilead Sciences (NASDAQ: GILD) CEO John Milligan laid out his top three priorities for 2018. Here's what he said (this and all other quotes courtesy of S&P....
Better Buy: AbbVie Inc. vs. Johnson & Johnson
Better Buy: AbbVie Inc. vs. Johnson & Johnson
They're partners. And they're rivals. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. However, the two big drugmakers compete against each....
Will UnitedHealth Group Do a Stock Split in 2018?
Will UnitedHealth Group Do a Stock Split in 2018?
Healthcare remains in flux, with changing policies concerning the Affordable Care Act and health insurance more broadly having a huge impact on the industry. As a leader in the health insurance....
Will UnitedHealth Group Do a Stock Split in 2018?
Will UnitedHealth Group Do a Stock Split in 2018?
Healthcare remains in flux, with changing policies concerning the Affordable Care Act and health insurance more broadly having a huge impact on the industry. As a leader in the health insurance....
3 Stocks That Have Doubled and Still Have Room to Grow
3 Stocks That Have Doubled and Still Have Room to Grow
The S&P 500 is hovering near an all-time high and has had a great year in 2017, so it's not a surprise that many stocks have delivered exceptional performance recently. However, just because a....
3 Stocks That Have Doubled and Still Have Room to Grow
3 Stocks That Have Doubled and Still Have Room to Grow
The S&P 500 is hovering near an all-time high and has had a great year in 2017, so it's not a surprise that many stocks have delivered exceptional performance recently. However, just because a....
3 Stocks That Have Doubled and Still Have Room to Grow
3 Stocks That Have Doubled and Still Have Room to Grow
The S&P 500 is hovering near an all-time high and has had a great year in 2017, so it's not a surprise that many stocks have delivered exceptional performance recently. However, just because a....
Is Merck & Co. Inc. a Buy?
Is Merck & Co. Inc. a Buy?
If 2017 ended right now, it would be the worst year for Merck & Co. (NYSE: MRK) stock since the financial crisis of 2008. There are still several weeks remaining before the year ends, of....
Is Merck & Co. Inc. a Buy?
Is Merck & Co. Inc. a Buy?
If 2017 ended right now, it would be the worst year for Merck & Co. (NYSE: MRK) stock since the financial crisis of 2008. There are still several weeks remaining before the year ends, of....
5 Lesser-Known Rule Breakers: Where We Stand at the 2-Year Mark
5 Lesser-Known Rule Breakers: Where We Stand at the 2-Year Mark
On this week's Rule Breaker Investing podcast, Motley Fool co-founder David Gardner reviews the performance of a set of his stock picks made up of companies most folks won't have heard of.Based on....
3 Biotech Stocks to Be Thankful for This Year
3 Biotech Stocks to Be Thankful for This Year
Anyone who has been holding onto shares of Loxo Oncology Inc. (NASDAQ: LOXO), Nektar Therapeutics (NASDAQ: NKTR), or Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) will have plenty to say when it's....